Matthew B. Lipner

638 total citations · 1 hit paper
7 papers, 452 citations indexed

About

Matthew B. Lipner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Matthew B. Lipner has authored 7 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Matthew B. Lipner's work include Chemotherapy-induced cardiotoxicity and mitigation (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). Matthew B. Lipner is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). Matthew B. Lipner collaborates with scholars based in United States, Switzerland and Germany. Matthew B. Lipner's co-authors include Julian Rosenman, Brian C. Jensen, Michael J. Eblan, Panayiotis Mavroidis, Thomas E. Stinchcombe, Timothy M. Zagar, Allison M. Deal, Kyle Wang, Mark A. Socinski and Lawrence B. Marks and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Matthew B. Lipner

6 papers receiving 447 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

2017 303 citations Kyle Wang, Michael J. Eblan et al. Journal of Clinical Oncology profile →

Peers

Matthew B. Lipner

PRM

RNMI

CCM

RADIA

ONCOL

Kathryn Banfill United Kingdom

Naomi B. Boekel Netherlands

K. Erven Belgium

Anhui Shi China

Enja J. Bantema-Joppe Netherlands

Veerle A.B. van den Bogaard Netherlands

G. Jimenez France

Neal S. McCall United States

Giorgio Pili Italy

Toni Vu Canada

Kathryn Banfill United Kingdom

Matthew B. Lipner

295 ×1.1

PRM

241 ×1.2

RNMI

124 ×0.8

CCM

158 ×1.1

RADIA

73 ×0.7

ONCOL

Citations per year, relative to Matthew B. Lipner Matthew B. Lipner (= 1×) peers Kathryn Banfill

Countries citing papers authored by Matthew B. Lipner

Since Specialization

Citations

This map shows the geographic impact of Matthew B. Lipner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew B. Lipner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew B. Lipner more than expected).

Fields of papers citing papers by Matthew B. Lipner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew B. Lipner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew B. Lipner. The network helps show where Matthew B. Lipner may publish in the future.

Co-authorship network of co-authors of Matthew B. Lipner

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew B. Lipner. A scholar is included among the top collaborators of Matthew B. Lipner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew B. Lipner. Matthew B. Lipner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Berginski, Matthew E., Brian T. Golitz, Matthew B. Lipner, et al.. (2024). Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. PeerJ. 12. e17797–e17797.

2.

Lipner, Matthew B., Xianlu L. Peng, Chong Jin, et al.. (2020). Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. JCI Insight. 5(8). 16–18. 24 indexed citations

3.

Wang, Kyle, Kevin A. Pearlstein, Allison M. Deal, et al.. (2017). Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiotherapy and Oncology. 125(2). 293–300. 89 indexed citations

4.

Wang, Kyle, Michael J. Eblan, Matthew B. Lipner, et al.. (2017). OA24.03 Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose-Escalation Trials Delivering 70-90 Gy. Journal of Thoracic Oncology. 12(1). S339–S340. 1 indexed citations

5.

Pearlstein, Kevin A., Panayiotis Mavroidis, Brian C. Jensen, et al.. (2017). Heart Dosimetric Analysis of Three Types of Cardiac Toxicity in Patients Treated on Dose-Escalation Trials for Stage III Non–small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 99(2). S152–S152. 5 indexed citations

6.

Wang, Kyle, Michael J. Eblan, Allison M. Deal, et al.. (2017). Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. Journal of Clinical Oncology. 35(13). 1387–1394. 303 indexed citations breakdown →

7.

Lipner, Matthew B., Raoud Marayati, Yangmei Deng, et al.. (2016). Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. PLoS ONE. 11(1). e0147113–e0147113. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact